Accurate Characterization by Dielectric Spectroscopy up to 25 GHz of Nano-liter Range Liquid Volume within a Microfluidic Channel

International audienceThis paper reports the design, simulation and experimental validation of an accurate liquid sensing technique in the nano-liter range. It is suitable for the detection and quantification of very small contents of liquid samples containing biological cells. The biosensor is based on an open-ended interdigitated capacitor (IDC) within a microfluidic channel. The microwave structure including the IDC is patterned in coplanar waveguide technology. The microfluidic channel is 100μm thick and the IDC covers an area of 150μm width and 90μm length. This leads to a volume under analysis much lower than a nano-liter which allows the noninvasive and contactless microwave investigation of biological cells in their culture medium. This micro-device is used to extract the complex permittivity of liquid media from the measured scattering parameters within the frequency band ranging from 0.2 to 25 GHz. For ease of use, a SMA-connectorized version of the device with spring contacts probes to the biosensor is also proposed. Results concerning microparticle detection within the media are also presented, extending the use of the sensors to cellular environments

Le cadmium en milieu marin : biogeochimie et ecotoxicologie

Programme IFREMER : Etudes en soutien a la definition des normesAvailable at INIST (FR), Document Supply Service, under shelf-number : 14435 C, issue : a.1989 n.16 / INIST-CNRS - Institut de l'Information Scientifique et TechniqueSIGLEFRFranc

Decontamination experimentale de bivalves toxiques : application aux phycotoxines paralysantes

Available from INIST (FR), Document Supply Service, under shelf-number : RP 185 (4018) / INIST-CNRS - Institut de l'Information Scientifique et TechniqueSIGLEMinistere de l'Environnement, 75 - Paris (France). Service de la Recherche et des Affaires Economiques (SRAE)FRFranc

Changement climatique et population

SIGLEAvailable at INIST (FR), Document Supply Service, under shelf-number : RP 185 (3930) / INIST-CNRS - Institut de l'Information Scientifique et TechniqueFRFranc

Gyrodinium cf. aureolum Recherche de facteurs toxinogenes, role des ectocrines et conditions de production

Available at INIST (FR), Document Supply Service, under shelf-number : RP 185 (2799) / INIST-CNRS - Institut de l'Information Scientifique et TechniqueSIGLEFRFranc

Dynamiques spatiales et temporelles de la reconstitution des peuplements de vers de terre dans des milieux en voie de regeneration

Comite Ecologie et Gestion du Patrimoine Naturel (EGPN), programme 'Dynamique de la biodiversite et gestion de l'espace'Available from INIST (FR), Document Supply Service, under shelf-number : RP 185 (4231) / INIST-CNRS - Institut de l'Information Scientifique et TechniqueSIGLEMinistere de l'Environnement, 75 - Paris (France). Service de la Recherche et des Affaires Economiques (SRAE)FRFranc

Conservation de la fertilite des sols tropicaux humides par l'introduction de vers de terre selectionnes - mise en place d'experiences a grande echelle

SIGLEAvailable at INIST (FR), Document Supply Service, under shelf-number : RP 185 (3199) / INIST-CNRS - Institut de l'Information Scientifique et TechniqueFRFranc

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Background: Faricimab is a bispecific antibody that acts through dual inhibition of both angiopoietin-2 and vascular endothelial growth factor A. We report primary results of two phase 3 trials evaluating intravitreal faricimab with extension up to every 16 weeks for neovascular age-related macular degeneration (nAMD). Methods: TENAYA and LUCERNE were randomised, double-masked, non-inferiority trials across 271 sites worldwide. Treatment-naive patients with nAMD aged 50 years or older were randomly assigned (1:1) to intravitreal faricimab 6·0 mg up to every 16 weeks, based on protocol-defined disease activity assessments at weeks 20 and 24, or aflibercept 2·0 mg every 8 weeks. Randomisation was performed through an interactive voice or web-based response system using a stratified permuted block randomisation method. Patients, investigators, those assessing outcomes, and the funder were masked to group assignments. The primary endpoint was mean change in best-corrected visual acuity (BCVA) from baseline averaged over weeks 40, 44, and 48 (prespecified non-inferiority margin of four letters), in the intention-to-treat population. Safety analyses included patients who received at least one dose of study treatment. These trials are registered with ClinicalTrials.gov (TENAYA NCT03823287 and LUCERNE NCT03823300). Findings: Across the two trials, 1329 patients were randomly assigned between Feb 19 and Nov 19, 2019 (TENAYA n=334 faricimab and n=337 aflibercept), and between March 11 and Nov 1, 2019 (LUCERNE n=331 faricimab and n=327 aflibercept). BCVA change from baseline with faricimab was non-inferior to aflibercept in both TENAYA (adjusted mean change 5·8 letters [95% CI 4·6 to 7·1] and 5·1 letters [3·9 to 6·4]; treatment difference 0·7 letters [-1·1 to 2·5]) and LUCERNE (6·6 letters [5·3 to 7·8] and 6·6 letters [5·3 to 7·8]; treatment difference 0·0 letters [-1·7 to 1·8]). Rates of ocular adverse events were comparable between faricimab and aflibercept (TENAYA n=121 [36·3%] vs n=128 [38·1%], and LUCERNE n=133 [40·2%] vs n=118 [36·2%]). Interpretation: Visual benefits with faricimab given at up to 16-week intervals demonstrates its potential to meaningfully extend the time between treatments with sustained efficacy, thereby reducing treatment burden in patients with nAMD